Adrenergic receptors regulate lipid mobilization, energy expenditure and glycogen breakdown. The b 2 adrenergic receptor (b 2 -AR) gene may constitute a potential candidate gene to explain part of the genetic predisposition to human obesity and correlated traits. With regard to the association between b 2 -AR gene polymorphisms and obesity-related metabolic disorders, published reports give conflicting results. We investigated the role of three polymorphisms, and related haplotypes of the b 2 -AR in the obesity and related traits in a cohort of overweight/obese subjects. We characterized one single nucleotide polymorphism (SNP) in the promoter region (5 0 LC-Cys19Arg) and two in the coding region (Gly16Arg and Gln27Glu) of the b 2 -AR in 642 consecutively recruited overweight/obese subjects in whom extensive clinical and biochemical analysis was performed. The effect of the polymorphisms on quantitative variables was investigated using multiple linear regression analysis. 5 0 LC-Cys19 homozygous showed higher triglyceride and LDL-cholesterol levels compared to 5 0 LC-Arg19 homozygous (P ¼ 0.03 and P ¼ 0.01, respectively). Similar increase in triglyceride and LDL-cholesterol levels was observed for Arg/Arg genotype compared to Gly/Gly genotype of Gly16Arg polymorphism (P ¼ 0.02 and P ¼ 0.01, respectively) and for Gln/Gln genotype compared to Glu/Glu genotype of the Gln27Glu polymorphism (P ¼ 0.01 and P ¼ 0.03, respectively). 
Adrenergic receptors regulate lipid mobilization, energy expenditure and glycogen breakdown. The b 2 adrenergic receptor (b 2 -AR) gene may constitute a potential candidate gene to explain part of the genetic predisposition to human obesity and correlated traits. With regard to the association between b 2 -AR gene polymorphisms and obesity-related metabolic disorders, published reports give conflicting results. We investigated the role of three polymorphisms, and related haplotypes of the b 2 -AR in the obesity and related traits in a cohort of overweight/obese subjects. We characterized one single nucleotide polymorphism (SNP) in the promoter region (5 0 LC-Cys19Arg) and two in the coding region (Gly16Arg and Gln27Glu) of the b 2 -AR in 642 consecutively recruited overweight/obese subjects in whom extensive clinical and biochemical analysis was performed. The effect of the polymorphisms on quantitative variables was investigated using multiple linear regression analysis . 5 0 LC-Cys19 homozygous showed higher triglyceride and LDL-cholesterol levels compared to 5 0 LC-Arg19 homozygous (P ¼ 0.03 and P ¼ 0.01, respectively). Similar increase in triglyceride and LDL-cholesterol levels was observed for Arg/Arg genotype compared to Gly/Gly genotype of Gly16Arg polymorphism (P ¼ 0.02 and P ¼ 0.01, respectively) and for Gln/Gln genotype compared to Glu/Glu genotype of the Gln27Glu polymorphism (P ¼ 0.01 and P ¼ 0.03, respectively). The 5 0 LC-Cys 19 Arg 16 Gln 27 haplotype determined a significant increase in triglyceride and LDL-cholesterol levels compared to 5 0 LC-Arg 19 Gly 16 Glu 27 haplotype (P ¼ 0.05 and P ¼ 0.02, respectively). Our findings provide additional weight to previous observations on the influence of these three genetic variants on lipid phenotypes; particularly on the increase of triglycerides and LDL-cholesterol levels in overweight/obese subjects carrying the 5
Introduction
The human b 2 adrenergic receptor gene (b 2 -AR) is encoded by a single intronless gene, located on the distal portion of the long arm of chromosome 5 (5q32 -q34).
Adrenergic receptors regulate lipid mobilization, energy expenditure and glycogen breakdown through endogenous catecholamines which are involved in the regulation of adipose tissue lipolysis, nonesterified fatty acid distribution, lipoprotein metabolism, glucose homeostasis, vascular tone and blood pressure.
1 Thus, the b 2 -AR gene may constitute a potential candidate gene to explain part of the genetic predisposition to human obesity and related traits. Genetic association studies have demonstrated an implication of b 2 -AR polymorphisms in various disease phenotypes: obesity and type 2 diabetes (T2DM), 2 metabolic syndrome, metabolic disorders 3,4 and hypertension. 5, 6 Several polymorphisms have been found in the coding region of b 2 -AR gene (Gly16Arg, Gln27Glu and Thr164Ile) and in the 5 0 leader cistron (5 0 LC-Cys19Arg) each of them leading to amino-acid substitution. 7 Gly16Arg and Gln27Glu alter cellular trafficking and receptor desensitization. 9, 10, 12 However, with regard to the association between these polymorphisms and obesity-related metabolic disorders, published reports give conflicting results including wide interethnic variation, gender-related differences and difference regarding the identity of the allele involved. 13 -20 In light of these considerations, we conducted a study, in a cohort of overweight/obese Italian subjects, to investigate the role of these three polymorphisms: 5 0 LC-Cys19Arg, Gly16Arg and Gln27Glu of b 2 -AR gene and related haplotypes in obesity and related traits.
Subjects and methods

Subjects
We studied 642 overweight/obese subjects (body mass index (BMI) 425 kg/m 2 ), who were consecutively recruited from the metabolic Day Hospital of the Department of Clinical Sciences of University of Rome 'La Sapienza'. Exclusion criteria were: previous diagnosis of diabetes according to ADA criteria, 21 chronic liver diseases and any treatment known to interfere with insulin sensitivity and metabolic syndrome-related parameters. All subjects signed a written consent to participate in the study. The study protocol was approved by the Ethical Committee of the University of Rome 'La Sapienza'. In all subjects BMI, blood pressure, waist circumference (measured midway between the lowest rib margin and the iliac crest) and hip circumference (measured over the great trocanthers) were measured as well as fasting glucose, insulin plasma levels and lipid profile (total, and HDL cholesterol and triglycerides).
Methods
Cholesterol and triglycerides concentrations were determined in plasma by Technicon RA-1000 Autoanalyzer; HDL was measured after precipitation of ApoB-containing lipoproteins with photungstic acid/MgCl 2 . LDL-cholesterol was determined by the Friedewald formula. 22 Glucose levels were calculated by the glucose oxidase method (Autoanalyzer, Beckman Coulter, USA). Plasma insulin was measured in frozen samples by radioimmunoassay (Adaltis insulin kit, Bologna, Italy), according to the manufacturer's instruction, with a limit of detection of o2.0 mU/ml.
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Insulin resistance status was estimated according to Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) following the formula previously described 24 :
fasting insulin (mcU/ml) Â fasting glucose (mmol/l)/22.5.
Nomenclature
The b 2 -AR transcription start site is 5 0 to a small ORF (termed the b 2 -AR 5 0 -Leader Cistron or 5 0 -LC) which encodes a 19-aa peptide and denotes the b 2 -AR upstream peptide (BUP). In this peptide it was found a polymorphism at amino-acid 19 (5 0 LC-Cys19Arg). N-terminal polymorphisms consist of substitutions of glycine for arginine at amino-acid position 16 (Cys16Arg) and glutamine for glutamic acid at position 27 (Gln27Glu).
Genotype analysis
The missense mutations 5 0 LC-Cys19Arg, Gly16Arg and Gln27Glu of b 2 -AR gene, were genotyped using the flurogenic 5 0 nuclease assay application of the ABI PRISM 7900 HT Sequence Detection System (ABI, Foster City, USA).
Genotyping of the 5 0 LC-Cys19Arg was performed using primers (0.9 mmol/l each) Forward 5 0 -CCGCTGAATGAGG CTTCCA-3 0 and Reverse 5 0 -CCATGGCGCGCAGTCT-3 0 and the TaqMan MGB probes Fam TCAGCAGGCGGAC and Vic TCAGCGGGCGGAC.
Genotyping of the Gly16Arg was performed using primers (0.9 mmol/l each) Forward 5 0 -GGCAGCGCCTTC TTGCT-3 0 and Reverse 5 0 -ACCCACACCTCGTCCCTTT-3 0 and the MGB probes Fam CCCAATGGAAGCCA and Vic CCCAATAGAAGCCATG. Genotyping of the Gln27Glu was performed using primers (0.9 mmol/l each) Forward 5 0 -GCGCCGGACCAC GAC-3 0 and Reverse 5 0 -CCACCACCCACACCTCGT-3 0 and the MGB probes Fam TCACGCAGGAAAG and Vic TCACG CAGCAAAG.
Of the 10 ng/ml stok of DNA 4 ml were dispensed into 384-well PCR plates using a Biomek FX robot (Beckman Coulter, Fullerton, USA) to which 6 ml of a mix containing primers, MGB probes and TaqMan Universal PCR Master Mix (ABI, Foster City, CA, USA) were added as per the manufacturers' instructions. These were sealed with optical seals (ABI, Foster City, CA, USA) and incubated for 951C 10 min followed by 40 cycles of 951C 15 s and 601C 1 min before analysis on a 7900HT plate reader (ABI, Foster City, CA, USA). 
Statistical analysis
Statistical analysis was performed using SPSS statistical software, version 12 (SPSS, Illinois, USA). Genotypic and allelic distributions were compared using the Pearson w 2 test. The effect of the polymorphisms on quantitative variables was investigated using multiple linear regression analysis.
We created two dummy variables to regress the three genotypes of each SNP; in order to incorporate genotypes as predictors in the multiple regression analysis and we decided to base the reference category on homozygote wild-type subjects. We adjusted the crude effect of the polymorphisms taking into account gender, age and BMI and we included triglycerides in the model as predictor of LDL-cholesterol (or vice-versa).
Data for insulin, triglycerides, HOMA-IR, were log 10 transformed to normalize their distribution. The frequencies haplotypes and the linkage disequilibrium matrix (LD) based on the D 0 parameter, were estimated using THESIAS (Testing Haplotype Effects in Association Studies) software. The objective of this program is to perform haplotype-based association analysis in unrelated individuals. THESIAS software is based on the maximum likelihood model described in Tregouet et al 25 and is linked to the SEM algorithm. 26 THESIAS also allowed the simultaneous estimation of haplotype frequencies and of their associated effects on the phenotype of interest. The estimate haplotype effects to the levels of biochemical variables are approximately half of the overall phenotypic mean. We adjusted the crude effect of the haplotype taking into account gender, age and BMI. We adjusted the P-values using Bootstrap method performing 1000 runs under the null hypothesis that no variant or haplotypes influence any trait tested. The bootstrap method creates pseudo-data sets by sampling observations with replacement from each within-stratum pool of observations. An entire data set is thus created, and P-values for all tests are computed on this pseudo-data set. A counter records whether the minimum P-value from the pseudo-data set is less than or equal to the actual P-value for each base test. This process is repeated a large number of times, and the proportion of resampled data sets where the minimum pseudo-P-value is less than or equal to an actual P-value is the adjusted P-value. Bootstrap analysis of the minimum P-values across all tests performed revealed that 20 of 1000 replicates (0.02) were less than the best nominal P-value observed in our studies. Therefore, we can reject the global null hypothesis: no SNP or haplotype are associated with any traits investigated.
Results
The genotype frequencies of 5 0 LC-Cys19Arg, Gly16Arg and Gln27Glu polymorphisms were in agreement with HardyWeinberg equilibrium (0.23, 0.4 and 0.5, respectively).
The allele frequencies of the three polymorphisms were: 0.33 for the 5 0 LC-Arg19, 0.4 for the Arg allele of Gly16Arg and 0.31 for the Glu allele of the Gln27Glu.
The 5 0 LC-Cys19 homozygous carriers showed higher levels of triglyceride and LDL-cholesterol compared to 5 0 LC-Arg19 homozygous (P ¼ 0.03 and P ¼ 0.01, respectively) ( Table 1) . A similar increase in triglyceride and LDLcholesterol levels was observed for Arg/Arg genotype compared to Gly/Gly genotype of Gly16Arg (P ¼ 0.02 and P ¼ 0.01, respectively) ( Table 1 ) and for Gln/Gln genotype compared to Glu/Glu genotype of the Gln27Glu (P ¼ 0.01 and P ¼ 0.03, respectively) ( (Table 3) . Moreover, the associated SNPs/haplotypes have independent influences on LDL-cholesterol and triglyceride levels.
The analysis of each SNP (Table 2 ) and related haplotype showed no statistically significant association with the other parameters investigated (data not shown).
Discussion
The present study shows a significant association between the three polymorphisms of b 2 -AR gene, 5 0 LC-Cys19Arg, Gly16Arg and Gln27Glu, and triglyceride and LDL-cholesterol plasma levels.
Results concerning the association of Gly16Arg and Gln27Glu polymorphisms of b 2 -AR gene and obesityrelated traits are conflicting; some studies found an association in the whole population, 3, 18, 30 others only in male 18,27 -29 or only in female populations.
14 Also the results on the identity of the allele involved in the association of Gly16Arg and Gln27Glu polymorphisms with lipid profile appear contradictory.
Meirhaeghe A et al 27 observed that the Glu allele determines lower triglyceride levels while they did not find any significant association with Gly16Arg polymorphism.
On the other hand, other studies pointed out that Gly and Glu variants are associated with obesity and related traits. 3,18,29 -31 In details, three previous studies found the Glu27 variant to be associated with higher triglyceride levels. 3, 30, 31 Two other studies found a similar association with higher LDL-cholesterol levels but did not observe any association with triglycerides. 18 Data are given as means and SD. All comparisons are adjusted for age, BMI and gender. P* ¼ Cys/Cys vs ArgArg; P1 ¼ Gly/Gly vs Arg/Arg; P } ¼ Gln/Gln vs Glu/Glu; P-values are adjusted using bootstrap method.
b 2 -AR gene and lipid profile A Petrone et al levels. It is, however, interesting to notice that other authors did not observe any association at all. 13, 15, 16, 20 These discrepancies and heterogeneity of the results can be explained by various factors such as: different genetic backgrounds, environmental factors and sex-related variables. Other influencing factors may be insufficient power or heterogeneity of the population studied in term of clinical phenotype (lean, obese) and different type of study (population based, clinical based).
The Regarding the Gly16Arg polymorphism, Large et al 36 found that terbutaline evoked a lipolytic response that was higher in Gly16 allele carriers compared to Arg16 homozygotes. Additionally, the Glu isoform of the Gln27Glu polymorphism, may be responsible for the altered ability of the receptor to be degraded by not being able to reach the mature wild-type conformation. 9 Furthermore, Arner et al 37 observed an inverse relationship between sensitivity and plasma triglyceride levels. Accordingly, Meirhaeghe et al 27 postulated that an accumulation of triglyceride levels in Gln27 carriers may be due to a less efficient lipolysis compared to Glu27 carriers; all the abovementioned observations seem to lead to the same direction of our results. A previous in vitro study showed that Gly16Arg and Gln27Glu polymorphisms have different properties of agonist-promoted downregulation. This downregulation appears to be significantly enhanced with the Gly16 variant; while the Glu27 variant shows to be strongly resistant. 9 However, the combination of the two variants displays enhanced downregulation showing that the Gly16 effects dominate the phenotype. 9 Rather conflicting results have been published on the ex vivo agonist promoted desensitization of these b 2 -AR isoforms. Chong et al 38 found that both mutant forms (Gly16 and Glu27) of the b 2 -AR were resistant to isoprenaline-induced desensitization compared to wild-type forms (Arg16 and Gln27), while an opposite result was also reported. 12 These alterations may be due to a different mechanism considering that ligand binding and functional activation of these receptors were not affected. It is not clear whether the different properties of agonistpromoted down-regulation, due to the two polymorphisms, could influence the lipolysis rate. Finally, it has been observed that the 5 0 LC-Cys19 variant determines consistently greater b 2 -AR expression levels as compared to cells expressing 5 0 LC-Arg19.
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In conclusion, despite a considerable amount of research on b 2 -AR coding SNPs, the results obtained by the different studies are often divergent. This inconsistency has more than one explanation. First of all, the findings are complicated by the unclear relation between the expression of the receptor, lipolysis and plasma triglyceride values. Functional studies showed the pharmacologic stimulation of the b 2 -AR does not change or even decrease plasma lipid levels 39 and low b 2 -AR sensitivity is linked to hypertriglyceridemia. 37 Second, because the presence of LD between SNPs and the different functional effects of the haplotypes created by these SNPs are potential sources of bias when studying different SNPs of the same gene, especially when all of them can be functionally relevant. Our findings provide additional weight to previous observations on the influence of these three genetic variants on lipid phenotypes, particularly on the increase of triglycerides and LDL-cholesterol levels in overweight/ obese subjects carrying the 5 0 LC-Cys 19 Arg 16 Gln 27 haplotype.
